Proteome Sciences (LON:PRM) Trading Up 0.6% – Still a Buy?

Proteome Sciences plc (LON:PRM)’s share price rose 0.6% on Monday . The company traded as high as GBX 2.30 and last traded at GBX 1.41. Approximately 248,823 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 464,412 shares. The stock had previously closed at GBX 1.40.

Proteome Sciences Price Performance

The stock has a market capitalization of £8.00 million, a PE ratio of -2.19 and a beta of 0.07. The stock’s 50 day moving average is GBX 1.56 and its two-hundred day moving average is GBX 1.93. The company has a debt-to-equity ratio of -165.46, a quick ratio of 0.37 and a current ratio of 0.13.

Proteome Sciences (LON:PRM) last issued its quarterly earnings results on Wednesday, April 15th. The company reported GBX (1.04) earnings per share for the quarter. The company had revenue of GBX 376 million during the quarter. Proteome Sciences had a negative net margin of 81.50% and a positive return on equity of 33.80%.

Proteome Sciences Company Profile

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.